This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

QIAGEN's CEO Hosts Investor Day - Conference Call Transcript


Investor Day Call

November 17, 2011 2:00 PM ET


John Gilardi –VP, Corporate Communications and Investor Relations

Peer Schatz – CEO

Helge Lubenow – VP and Head of Molecular Diagnostics Business

James Mahony – Head, Regional Virology, McMaster University

Roland Sackers – CFO

Ellen Sheets – Chief Medical Officer

Stephen Little – VP, Personalized Healthcare

Veena Singh – MD, bioTheranostics


John Gilardi

Good afternoon. If you’ll please take your seats, we’re ready to start the event. There are some seats still here in the front that are open.

I’m John Gilardi, Vice President of Corporate Communications and Investor Relations at QIAGEN. I’d like to welcome all of you to our Annual Analyst and Investor Day. We have about 50 participants here in the room in Dallas, and as you know, our event is being held here at the Annual Meeting of the Association for Molecular Pathology, or AMP.

I want to thank all of you who made the trip to be here with us in Texas, and we’d also like to thank AMP for their support and letting us hold this event here at their venue. For those of you on the webcast, I’d like to also thank you as well for joining our event, particularly those of you in Europe where it’s now evening.

A replay will be available, starting on Friday, on the “Investor Relations” section of our homepage, at, and documents for this event are also available on our website. Today, we want to provide you with insights into our business activities and, in particular, Molecular Diagnostics. But, also, we wanted to give you an opportunity to hear from some of our customers.

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.41 -1.50%
FB $116.31 -0.36%
GOOG $692.92 0.27%
TSLA $239.45 -3.30%
YHOO $36.36 -0.63%


Chart of I:DJI
DOW 17,701.60 -129.16 -0.72%
S&P 500 2,059.78 -16.03 -0.77%
NASDAQ 4,765.0410 -40.25 -0.84%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs